MiniMed Group, Inc.
MMED
Analytical Summary
MiniMed Group, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
- Profit Margin (%)Profit Margin (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2026 Apr 24, 2026 10-K ↗ | FY 2025 Apr 25, 2025 10-K ↗ | FY 2024 Apr 26, 2024 10-K ↗ | FY 2023 Apr 28, 2023 10-K ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
14.3%
Good
Good
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+78%)
|
10.0%
Fair
Fair
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+25%)
|
— | — |
| EPS Growth YoY (%) |
-54.8%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
-90.9%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-56.3%
Weak
Weak
Year-over-year change in net income |
-90.2%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-680.7%
Weak
Weak
Year-over-year change in free cash flow |
50.5%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2026 Apr 24, 2026 10-K ↗ | FY 2025 Apr 25, 2025 10-K ↗ | FY 2024 Apr 26, 2024 10-K ↗ | FY 2023 Apr 28, 2023 10-K ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) |
-6.1%
Weak
↓
Weak
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-141%)
|
-5.4%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-136%)
|
-2.8%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-119%)
|
— |
| Effective Tax Rate (%) (%) |
-67.7%
Excellent
↓
Excellent
Declining
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-35.4%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-54.3%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| Profit Margin (%) (%) |
-10.7%
Weak
↓
Weak
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-189%)
|
-7.8%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-165%)
|
-4.5%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-138%)
|
— |
| FCF Margin (%) (%) |
-13.5%
Weak
↓
Weak
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-2.0%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-4.3%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
1.26x
Good
↑
Good
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.25x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.96x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2026 Apr 24, 2026 10-K ↗ | FY 2025 Apr 25, 2025 10-K ↗ | FY 2024 Apr 26, 2024 10-K ↗ | FY 2023 Apr 28, 2023 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-8.8%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-5.9%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-3.1%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-4.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-3.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — |
| Return on Common Equity (%) (%) |
-9.2%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-161%)
|
-6.4%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-143%)
|
-3.2%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-122%)
|
— |
| Metric | FY 2026 Apr 24, 2026 10-K ↗ | FY 2025 Apr 25, 2025 10-K ↗ | FY 2024 Apr 26, 2024 10-K ↗ | FY 2023 Apr 28, 2023 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $3.10B | $2.71B | $2.47B | — |
| Depreciation Expense (USD) | $156.00M | $143.00M | $129.00M | — |
| Net Income, GAAP (USD) | $-333.00M | $-213.00M | $-112.00M | — |
| Operating Cash Flow (USD) | $-197.00M | $140.00M | $41.00M | — |
Secondary lens
Benchmark Lens
Compare MMED against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare MMED against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for MMED
No bullish signals detected
Operating Margin (%) is in the bottom quartile
Profit Margin (%) is in the bottom quartile
Percentile Rankings
How MMED compares to all companies
Peer Comparison
MMED vs similar peers
Compare MMED with peers
Stack MMED against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 12 quarters